Current Report Filing (8-k)
February 08 2019 - 5:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current
Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 7, 2019
WRIGHT MEDICAL GROUP N.V.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
The Netherlands
|
|
1-35065
|
|
98-0509600
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
Prins Bernhardplein 200
1097 JB Amsterdam
The
Netherlands
|
|
None
|
(Address of principal executive offices)
|
|
(Zip code)
|
(+31) 20
521-4777
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the
Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or
Rule
12b-2
of the Securities Exchange Act of 1934. (17 CFR
240.12b-2).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an
Off-Balance
Sheet Arrangement of a Registrant.
On February 7, 2019, Wright Medical Group, Inc.
(
WMG
), an indirect, wholly-owned subsidiary of Wright Medical Group N.V. (the
Company
), issued $139,556,000 additional aggregate principal amount of WMGs 1.625% cash convertible senior notes due 2023
(the
2023 Notes
and, such additional aggregated principal amount, the
Additional 2023 Notes
) pursuant to an indenture, dated as of June 28, 2018 (the
Indenture
), among WMG, the Company
and The Bank of New York Mellon Trust Company, N.A., as trustee (the
Trustee
). The Additional 2023 Notes were delivered upon settlement of previously announced privately negotiated exchange agreements among the Company, WMG and a
limited number of investors who are accredited investors (within the meaning of Rule 501 promulgated under the U.S. Securities Act of 1933, as amended (the
Securities Act
)) and/or qualified institutional buyers (as defined in Rule
144A under the Securities Act), pursuant to which such accredited investors and/or qualified institutional buyers exchanged $130,134,000 aggregate principal amount of WMGs existing 2.00% cash convertible senior notes due 2020 (the
2020 Notes
) for the Additional 2023 Notes. Following the exchange, the aggregate outstanding principal amount of the 2023 Notes is $814.6 million and the aggregate outstanding principal amount of the 2020 Notes is
$56.5 million.
The Additional 2023 Notes are fully and unconditionally guaranteed by the Company on a senior unsecured basis. The
Additional 2023 Notes will pay interest at a rate of 1.625% per year, payable semiannually in arrears on June 15 and December 15 of each year, and will mature on June 15, 2023, unless earlier converted or repurchased. The Additional
2023 Notes have the same terms, and were issued under the same Indenture, as the 2023 Notes issued on June 28, 2018, as described in the Companys Current Report on
Form 8-K
filed with the
Securities and Exchange Commission on July 3, 2018 (the
Prior Form
8-K
). The information set forth in the Prior
Form 8-K
is incorporated herein by reference.
The foregoing description of the Indenture and
the Additional 2023 Notes does not purport to be complete and is qualified in its entirety by reference to the form of note representing the Additional 2023 Notes, which is filed as Exhibit 4.1 to this Current Report on Form
8-K,
and the Indenture, which is filed as Exhibit 4.1 to the Prior Form
8-K,
each of which is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
WRIGHT MEDICAL GROUP N.V.
|
|
|
|
|
Dated: February 8, 2019
|
|
|
|
By:
|
|
/s/ Lance A. Berry
|
|
|
|
|
|
|
Lance A. Berry
|
|
|
|
|
|
|
Executive Vice President, Chief Financial and Operations Officer
|
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Jul 2023 to Jul 2024